Skip to content

PUSHING THE BOUNDARIES

At Kodiak, we are working to develop disruptive products and platforms to prevent and treat the leading causes of blindness

ABC PLATFORM


We are bringing new science to the design and development of next generation retina medicines, starting with our ABC Platform  

1 Molecule, 1 Target

tarcocimab tedromer (KSI-301): inhibits VEGF for retinal vascular diseases

1 Molecule, 2 Targets

KSI-501: dual inhibition of IL-6 (anti-IL-6 antibody) and VEGF (VEGF-Trap) for patients that historically do not respond well to anti-VEGF alone

1 Molecule, 3 Targets

KSI-601: for multifactorial diseases, such as dry AMD and glaucoma

PRECISION ENGINEERED FOR INCREASED DURABILITY AND EFFICACY


Designed for the retina, the ABC platform uses our bio-inspired polymer to orchestrate water around a purpose-built antibody to power new and enduring capabilities in retina care

1 or 2 Targets

Biopolymer

Optically clear, branched, high-molecular weight phosphorylcholine polymer.

It binds to water to create a water force-field around the antibody. This shields it from non-specific interactions and allows it to focus on its target.

Stable, Single-Site Specific Linkage

Stable, site-specific linkage that is non-degradative and non-erodible. The bioconjugate enters and exits the eye intact leaving no residual material.

IgG1 Antibody

Engineered to bind to its target with high specificity and to be immune silent. Designed for 1 or 2 targets.

3 Targets

Revolutionizing treatment of multifactorial retinal diseases with triplet medicines

Our triplet medicines combine the benefits of our ABC Platform with the sustained release of 100’s of small molecules to impact three mechanisms of disease enabling treatment of complex disorders such as dry AMD.

Bispecific Antibody

Conjugated to phosphorylcholine biopolymer designed for improved durability, excellent retinal bioavailability, and rapid systemic clearance.

New, single molecule

Designed for retinal diseases to modulate multiple intracellular and extracellular disease pathways.

Small-molecule drug

Embedded and attached into the phosphorylcholine biopolymer and designed for high biocompatibility, high drug loading, and sustained release.

BUILT TO DIFFERENTIATE AND ENDURE


The ABC Platform has a high molecular weight and formulation strength. This can provide an important dosing advantage

Equivalent values are shown as fold changes relative to aflibercept. kDa= kilodalton.
†Lower affinity of bevacizumab precludes a useful comparison.
‡Assumes 2x starting molar dose and similar ocular T1/2 as aflibercept

TARCOCIMAB TEDROMER (KSI-301): GENERATION 2.0 ANTI-VEGF RETINAL MEDICINE


Same Where It Matters

  • Clinically proven targets
  • Antibody-based biologic
  • Intravitreal: safest method of administration
  • Optically clear, no residues
  • Fast and potent clinical responses

Different Where It Counts

  • Designed-in ocular durability
  • Designed-in rapid systemic clearance
  • Improved bioavailability
  • Improved biocompatibility
  • Improved stability

MORE THAN THE SUM OF ITS PARTS


The ABC Platform structures water at critical binding interfaces to make medicines last longer in the eye and improve their therapeutic benefit

Remarkable Intraocular Half-life

Medicines built on the ABC Platform (e.g., KSI-301) last longer and better maintain therapeutic concentration levels in the eye

Excellent Retinal Bioavailability

The ABC Platform improves therapeutic absorption and distribution in the eye

Deeper Inhibitory Potency

The ABC Platform binds and inhibits VEGF in a more relevant way

Fast Systemic Clearing

The ABC Platform is designed to clear the body quickly after it exits from the eye

TAKE A 3-DIMENSIONAL TOUR


Tour our Antibody Biopolymer Conjugate (ABC) PlatformTM in 360° below.

Click and drag to see different views. Scroll or pinch to zoom.

Please be patient while the 3-D model loads